|Videos|December 11, 2020
Implications of Expanding Use of CAR T-Cell Therapy in Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)
A discussion on the clinical impact of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractor (R/R) non-Hodgkin lymphoma and the role of expanding CAR T administration into the community practice setting.
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Rapid Therapeutic Effects Seen With a JAK Inhibitor
September 17th 2025
- SALT Scoring for Alopecia Areata
September 17th 2025
- The Potential Role of Screening for Atrial Fibrillation
September 16th 2025
- Remote Patient Monitoring and Artificial Intelligence
September 16th 2025
- Access, Adaptation, and Cost-Effectiveness in AD Treatment
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5